We are often asked about GP stakes – transactions in which a private equity or venture capital firm sells a minority interest in its own management business to an outside investor. In our primer on structuring the general partner and management company, we described the management company as the 100-year entity: the firm itself, built to outlast any fund and any founder. This primer is about what happens when someone offers to buy a piece of it – an offer that has migrated, over 15 years, from exotic to routine at the industry’s summit, then down into the middle market where most of our readers live, and now, tentatively but unmistakably, into venture capital. The transaction forces a question most partnerships have never had to answer out loud: Is this firm a collection of people who share economics, or an institution with an equity value of its own? Everything in a GP stakes deal – the price, the terms, the investor conversation, the internal aftermath – is downstream of how honestly that question gets answered.
First, a scope note, because “buying into a manager” describes several different transactions. Our subject is the minority, non-control investment in the management business itself – the management company and, typically, participations in the general partner entities’ carried interest – whether made by a dedicated GP stakes fund, a sovereign or strategic investor, or an insurance balance sheet. We are not speaking of an investor buying limited partnership interests in the firm’s funds (that is just investing), nor of continuation vehicles (a fund-level transaction), nor – except for occasional contrast – of outright acquisitions of managers, which are corporate M&A with different physics. And we are not speaking of seeding, the launch-stage cousin in which firm economics are exchanged for existence itself; that transaction has its own primer, and the two markets are converging from opposite ends of a firm’s life – seeding buys into the firm before the market believes; stakes buy in after it does.
A second scope note, and really the thesis of this primer: A GP stake monetizes the one asset a fund manager’s investors were told was priceless – alignment. The buyer is purchasing a share of the management fees and carried interest that exist, in the official theory of this industry, to keep the manager hungry and bound to its investors’ outcomes. Selling a slice of that stream is not inherently a betrayal of the theory; done one way, it strengthens it, and we will show the arithmetic. But it is always a transaction about the theory, which is why the single most important term in any GP stakes deal is not the price or the percentage. It is the use of proceeds – because what the money does determines whether the firm has pre-funded its next 50 years or cashed out its first 30, and every constituency that matters, from the limited partners to the youngest partner on the letterhead, will read the answer fluently.
At a high level, three questions determine almost everything about a GP stakes transaction:
- What exactly is being sold? “Fifteen percent of the firm” is a sentence that conceals a dozen decisions: which entities, which revenue streams, which fund vintages, whether future funds are included, whether the balance sheet comes along. The perimeter is the deal, and drawing it is most of the work.
- What will the money do? GP commitments to the next funds, buyouts of retiring founders, seed capital for new strategies, founder diversification – each is a legitimate answer with a different price in the currency of investor confidence, and the mix should be decided before the process begins, because it is the story.
- What does the buyer get besides economics – and how does it end? “Passive minority investor” is the category’s marketing; the consent list is the fact. And because these positions are held in largely perpetual vehicles, the deal being signed will outlive most of the people signing it, which makes the exit and transfer mechanics, negotiated at the entrance, the terms the firm’s next generation will actually live with.
These questions are related, but they are not the same. A firm can draw the perimeter perfectly and still tell the wrong story about the proceeds. We will build up to all three, but first, some terminology.
A note on terminology
A few terms recur throughout this post and reward precision.
A GP stake is a minority equity or economic interest in a fund sponsor’s management business – confusingly named, since what is sold usually includes the management company (the fee-earning, people-employing 100-year entity) together with participations in the general partner entities that receive carried interest, fund by fund. (For the architecture of those entities and why they are separate, see our primer on structuring the general partner and management company; it is the map on which this transaction’s perimeter is drawn.)
The buyer’s underwriting vocabulary matters because it becomes the seller’s valuation vocabulary. FRE (fee-related earnings) is the profit stream from management fees and other contractual revenues, net of the operating costs of producing them – the durable, visible, contracted cash flow that this market prizes most and prices highest. PRE (performance-related earnings) is the carry stream – larger in expectation, lumpy in fact, and valued accordingly at a discount to its fee-based sibling. DE (distributable earnings) is the blended cash measure. A stakes fund is a dedicated vehicle formed to buy such interests, typically structured as permanent capital – long-dated or perpetual, distributing the acquired cash flows quarterly – which is why the exit question shadows the entire category.
Primary proceeds go into the firm – GP commitments, growth, balance sheet; secondary proceeds go to the selling owners. The distinction is the load-bearing wall of the investor conversation. Consent rights (or negative controls) are the buyer’s list of things the firm cannot do without asking – the measure of how passive “passive” really is – alongside information rights, transfer restrictions, tag and drag mechanics, anti-dilution protections, key person undertakings and buyback rights. An earn-in or ratchet adjusts the buyer’s percentage against future performance, the standard bridge across valuation gaps; a holding company structure interposes a single entity through which the buyer holds its interests across the firm’s entities – cleaner for the buyer, more consolidating for the firm. And assignment, in the Advisers Act sense, is the regulatory word for a change of control of an adviser – the reason minority sizing is not just an economic choice, discussed below.
The market: From exotic to infrastructure
The category is young enough that its whole history fits in a career. Dedicated minority stakes investing in alternative managers emerged in the years around the financial crisis, was institutionalized through the 2010s by a small number of pioneering platforms, and by the turn of this decade had produced listed vehicles, multibillion-dollar flagship funds and a settled playbook. The scale is now considerable: Dedicated stakes managers have collectively raised on the order of $100 billion dollars; the largest single fund in the category closed near $13 billion; the largest single transaction approached $2 billion for a stake in one manager; and by market counts, a quarter of institutional investors now hold at least one stakes fund in their portfolios. Recent-year deal value has run north of $20 billion dollars annually, with transaction volume by one leading adviser’s count jumping 40% in the most recent year.
Two structural shifts define the current market, and both matter to this blog’s readers more than the headline numbers. The first is the move down-market. The earliest deals went to the industry’s largest franchises, but the center of gravity has migrated decisively to managers in the low-to-mid single-digit billions of assets – firms facing a harder fundraising environment, first-generation founders approaching transition, and more to gain from a capitalized partner – served by a widening field of mid-market specialists and a wave of new entrants founded by veterans of the pioneer platforms. What was a bulge-bracket product is now a mid-market conversation, which is to say: It is now most managers’ conversation.
The second shift is that the market has begun to age into its own hardest question. Stakes were built as buy-and-hold-forever positions in perpetual vehicles; the first genuine exits have now printed – stakes sold between stakes platforms, stakes resolved through strategic acquisitions of the underlying managers – and buyers increasingly arrive with liquidity plans, structured elements and continuation-style solutions of their own. A seller today should assume its minority partner will, someday, be a different minority partner, and negotiate the transfer provisions with that assumption out loud.
One more market note: The modern buyer sells more than money. The established platforms compete on value-add – limited partner introductions and capital-formation support above all, plus business-services benches covering the unglamorous functions – and, at the mid-market, where a firm’s investor-relations infrastructure is thin, the buyer’s distribution network can genuinely be worth more than the check. Like every such promise in this industry, it should be diligenced in commitments closed rather than meetings taken; the better platforms will show you.
The seller’s process: How these deals actually happen
Most stakes transactions begin with an inbound – a term sheet or a lunch – which is precisely why the prepared firm outperforms the courted one: the moment to decide whether, why and on what terms to sell is before the flattering call, not during it. The process itself has converged on a recognizable shape. A specialist adviser (this is now a banked market, with dedicated coverage) runs a quiet, narrow auction among a handful of logical buyers; breadth is the enemy here, because the diligence materials are the firm’s crown jewels, and every additional bidder is another institution holding them. The heaviest lift surprises first-time sellers: The firm has never had financial statements an outsider could read. Management company books built for the partners’ own purposes must be rebuilt into a diligence-grade presentation – fee-related earnings constructed and bridged to actuals, partner compensation normalized (a genuinely uncomfortable exercise, since the buyer’s model treats the partners’ pay as a cost line to be interrogated rather than a residual to be enjoyed), fund-by-fund carry projections assembled, adjustments documented. Expect the preparation to take a quarter and the process two more, with exclusivity granted late and grudgingly. And run the internal communications as deliberately as the external ones: In most firms, only a small circle knows until late, the wider partnership learns in a managed sequence, and the difference between a partnership that hears “we sold 15% to fund the future” from its founders and one that hears it from a reporter is the difference between a financing and a wound.
Why firms sell: The use-of-proceeds taxonomy
Everything in the investor conversation, and most of the internal one, flows from what the money is for, so we will take the four honest answers in descending order of how easily they defend themselves.
Funding the GP commitment. The cleanest story, and increasingly the most common. Success has an arithmetic problem: As funds grow, the general partner’s own commitment grows with them – investors insist on it, correctly, as the core of alignment – and the partners’ personal balance sheets, however healthy, eventually cannot keep pace with a flagship that has tripled. Stake proceeds deployed into the firm’s own funds convert the transaction’s optics entirely: The firm sold a share of its fee stream to put more of its own capital at risk alongside its investors, which is not a dilution of alignment but a purchase of it. When the use-of-proceeds story is this one, quantified, the limited partner conversation tends to be short.
Funding the generational transition. The second-cleanest story, and the one the demographic wave is making urgent: A founding generation approaching its exits, a next generation that cannot write nine-figure checks to buy them out, and a partnership that would otherwise fund succession with debt loaded onto the people least able to bear it. A stake sale can capitalize the transition: Retiring founders receive value for what they built; continuing partners take larger economics without mortgaging themselves; and the buyer underwrites the next generation’s firm, which is precisely the bet stakes investors say they want to make. This is the transaction as succession instrument, and it connects directly to our primers on planning for and handling senior partner transitions: The stake sale is, among other things, the financing leg of the bridge those primers describe.
Funding growth. Balance sheet for launching adjacent strategies, seeding new products, building distribution, occasionally acquiring teams – the firm as a company making capital investments in itself. Legitimate and common, with one discipline: The growth story should be specific enough to be checked later, because “strategic flexibility” is the use-of-proceeds equivalent of a blank endorsement, and both the buyer and the limited partners will remember what was said.
Founder liquidity. The delicate one, so let us be direct rather than euphemistic: Some portion of many stakes deals is secondary – founders converting a slice of illiquid franchise value into money – and the market has learned to live with it in moderation. The keys are proportion and candor. A transaction that is mostly primary with a disclosed secondary component reads as owners of a valuable business behaving like owners of a valuable business; a transaction that is mostly founders cashing out, dressed in growth language, reads as exactly what it is, and the constituencies that matter – the buyer underwriting founder motivation, investors underwriting alignment, young partners underwriting their own futures – will each independently do the math. The practitioner’s checklist for the investor narrative has four standing questions, and every seller should be able to answer them before the process starts: day-to-day control is unchanged; here is the primary-versus-secondary split; here is why the key people remain incentivized notwithstanding any windfall; and here is the carry the team still holds, quantified. Firms that can answer crisply sell stakes without drama. Firms that cannot should fix the answers before, not after, running the process.
One discipline belongs before the taxonomy is applied: the alternatives memo. Each of the four purposes has nondilutive competition, and a partnership should be able to say why the stake beat it. GP commitments can be financed – capital-call facilities, management-fee waivers, personal lending against carry – at a cost measured in interest rather than perpetuity. Founder buyouts can be funded internally with seller notes and extended buy-in schedules, slower and cheaper than external capital, at the price of the next generation’s leverage. Growth can be bootstrapped from retained fee earnings, if the partnership can tolerate distributing less – which is itself the honest question a stakes process often exists to avoid asking. And diversification can wait. Sometimes the memo concludes for the stake anyway, and often rightly: The alternatives load risk onto individuals that an institution should carry, and the buyer’s capital arrives with validation and distribution the alternatives lack. But the memo should exist, because the first question a sophisticated limited partner asks about a stake sale is some version of “what else did you consider?” – and “nothing; they called us” is an answer with a long half-life.
What is being bought, and how it is priced
The asset being sold is a bundle of contractual cash flows plus a call option on the franchise’s future, and the pricing logic follows that decomposition. The fee stream prices richest: Fee-related earnings are contracted, visible for a decade at a time on committed-capital funds, and the market’s valuation anchor – for reference, research on the publicly traded managers has applied FRE multiples averaging in the low 20s, within a wide band, with the highest-FRE-proportion firms commanding the highest values. Carry participations price lower and messier: larger in expectation, dependent on realizations, cyclical, and – critically – valued differently depending on whose work will earn them, which is why buyers care intensely whether they are purchasing carry in existing vintages (harvesting others’ seeds) or future funds (a bet on the go-forward team). The balance sheet, where included, prices at asset value. Blending these into a headline number is a technical exercise on projections of the one thing nobody controls – future fundraising – which is why valuation gaps are chronic and the standard bridge is structure: earn-ins and ratchets that flex the buyer’s percentage against fund sizes actually raised, deferred components, and revenue-based elements at the smaller end.
Then the perimeter, which deserves more founder attention than the multiple. Which entities are inside – the management company only, or the general partner carry vehicles too, and for which funds? Are future funds and future strategies automatically included, or does the buyer’s percentage attach only to what exists, with new businesses negotiated (the seeding primer’s scope lesson, replayed at scale)? Where does the firm’s own balance sheet investing sit? Is the stake at a holding company that consolidates everything – cleaner for the buyer, more entangling for the firm – or entity by entity? Every one of these choices moves value, governance and, not incidentally, taxes. The diligence around how fees and carry actually flow through the structure, what the state-tax footprint looks like, and what a buy-in does to basis and character is genuinely technical, and the deal team should include the tax advisers from the first whiteboard rather than the last turn of the model.
The instrument itself has a menu beyond common equity, and the choice telegraphs intent. Straight common interests – sharing ratably in good years and bad – make the cleanest alignment statement. Preferred features have crept in from the buyer side, particularly at the mid-market: minimum quarterly distributions, priority returns, distribution policies with teeth – each one converting the buyer, by degrees, from partner toward creditor, and each one a term the firm’s future leadership will service in lean years. Debt-like and hybrid structures (financing against the fee stream rather than selling it) occupy the adjacent market and suit sellers whose objection is to permanence rather than to leverage. At the smaller end, revenue share-only deals – stakes-lite, without equity’s governance – mirror the seeding market’s tools, which is no coincidence given where the two markets are converging. And the future funds question runs through every structure: whether the buyer’s carry participation attaches automatically to Funds N+1 and beyond, at flat or stepped percentages, or must be re-earned – the single term that most determines whether the firm sold a snapshot or subscribed its future.
And one internal consequence sellers underestimate: The deal prints a number. A firm that has never been valued now has a market price, established by a sophisticated third party, and that number walks straight into every internal conversation the partnership was previously able to keep vague – admissions, retirements, buy-sell provisions, estate planning, the departing partner’s settlement. Our primer on the general partner and management company described those internal mechanics; a stakes transaction is the event that forces them all to be marked to market. Prepare the partnership for that before signing, because the valuation cannot be unprinted.
What the buyer is actually underwriting
It pays for the seller to understand the buyer’s model, because the model is where the price comes from and – a side benefit sellers rarely anticipate – because seeing your firm through a professional owner’s spreadsheet is the most useful consulting engagement most partnerships never commissioned. The model’s engine is fundraising: The stake’s value is overwhelmingly a bet on future funds being raised at growing scale, which is why the buyer’s diligence lives in your investor relationships (re-up rates, concentration, the health of the top 10), your fundraising history against targets, and your capacity story – and why sellers with a flagship mid-raise or freshly closed command the best prices and cleanest processes. Around the engine sit the durability checks: team depth beneath the founders (the succession the buyer is partly financing had better be visible in the org chart); net-flow and realization patterns; strategy capacity, since a buyer underwriting growth has no interest in a firm whose alpha degrades with scale; the expense base and its trajectory, partner compensation included; and the franchise intangibles – brand, references, the groundwater – which the better buyers diligence through the same LP channels the seller’s next fundraise will travel. Sellers should run the buyer’s model on themselves before the process starts, honestly, because every weakness it surfaces will be surfaced, priced and papered anyway – and a firm that discovers its own concentration problem in a bidder’s markdown has paid full tuition for information that was free.
What the buyer really gets: Passive is a posture, the consent list is the fact
The category’s self-description – passive, non-control, alongside management – is true as far as it goes, and the direction of travel is worth stating plainly: It goes less far every year. In the current market, it is rare for even a 10% investor to arrive without consultation rights and a schedule of negative consents, and the standard list has converged: consent over sales of the firm or additional stakes; over new business lines and, sometimes, new fund launches outside the existing strategy; over extraordinary distributions and departures from agreed distribution policies; over incurrence of debt at the management company; over amendments to the governing documents that touch the buyer’s economics; frequently over budget frameworks; and always over anything that dilutes.
Around the consents sit the protective architecture – anti-dilution provisions, transfer restrictions running both directions, tag and drag mechanics, robust information rights – and the people terms: key person undertakings binding named founders, lock-ups on their equity, noncompetes, and buyback or put/call machinery for the paths nobody plans. None of this is control, and the buyers are genuinely careful to stay on the right side of that line for their own regulatory and portfolio reasons. But a founder should read the consent list twice – once as today’s management, for whom every item seems reasonable, and once in the voice of the firm’s leadership in year 15, who will encounter this document as an inheritance, negotiated by predecessors, held by a buyer who may itself have transferred the position by then. The terms that protect a minority investor and the terms that quietly constrain a firm’s evolution are the same terms – calibration, not elimination, is the negotiation.
Two people-terms deserve their own sentence. Key person and noncompete provisions sized to today’s founders can, if drafted carelessly, strangle exactly the succession the transaction was supposed to fund – the next generation needs room to be promoted into significance, and the covenants should be built to migrate. And the buyback: As in seeding, a negotiated repurchase path – triggers, formula, funding mechanics – is the single most valuable clause a seller can obtain, because it converts a perpetual marriage into one with a priced exit, and it is dramatically cheaper to obtain while the buyer is competing for the deal than at any moment afterward.
After the closing: Living with a minority partner
The deal takes months; the relationship takes decades, and its texture is worth previewing. The steady state is undramatic by design: quarterly reporting against agreed formats, distributions on the negotiated policy, an annual budget conversation whose temperature depends entirely on how the expense and compensation frameworks were drafted, sometimes a board observer, and access to whatever value-add platform was part of the pitch – which the well-advised firm actually uses, having paid for it in perpetuity. The frictions, when they come, arrive on schedule. The next flagship raise is the first: the buyer’s earn-in or ratchet mechanics reprice against the outcome, its capital-formation help is tested against its marketing, and any linked fund commitment matures from closing sweetener into live negotiation. Strategic inflection points are the second: the new product, acquisition, succession event – each one traveling through the consent list negotiated years earlier by people optimizing for a different moment. And the platform conflicts are the third: a dedicated stakes buyer owns interests in many managers, occasionally in strategies adjacent to yours, and the information rights that seemed innocuous at signing – pipeline visibility, LP-level data, economics – are held by an institution with a portfolio-wide view; walls and use restrictions earn their drafting here exactly as they do in the seeding market.
None of this is a warning against the category. It is a reminder that the term sheet is a forecast of a relationship, and the sellers who fare best negotiated it as one – tight where the incentives diverge, generous where they align, and reviewed, every few years, by someone asking what the document now does rather than what it once meant.
The internal transaction
Every stakes deal is two transactions, and the internal one – among the partners – is routinely the harder. Start with who sells. Secondary proceeds must be allocated across a partnership whose members hold different vintages of equity, different expectations and different needs: Founders-only secondaries are common and defensible (they built the value being sold) but must be handled in the open, because a junior partner who discovers the seniors’ liquidity event from the closing dinner has learned something about the firm no retention grant fully unteaches. Pro-rata participation is cleaner and rarer; hybrid approaches – founders sell, continuing partners receive enlarged go-forward economics funded by the same transaction – are often the honest middle.
Next, compensation. The buyer’s diligence normalizes partner pay as an expense line in the FRE model, and the partnership discovers that its most private subject is now a third party’s spreadsheet input – with consequences. Comp philosophy gets documented, sometimes for the first time; employment and restrictive covenant agreements arrive at firms that ran for decades on handshakes; and the distribution-versus-reinvestment decision, formerly a December conversation, becomes a governed policy with a counterparty.
Then tax, at altitude only: The character and basis consequences of selling interests in fee- and carry-generating entities differ by structure and by seller, installment and rollover features are common, and the difference between the architectures is measured in real percentage points – tax counsel joins at the term sheet, not the signing.
Finally, the deal changes the firm’s internal market permanently, in the manner flagged above: A printed valuation converts every future admission, retirement and buy-sell negotiation from a discussion into a mark-to-market. The firms that fare best treat the internal transaction as a design object of equal rank with the external one – decided, documented and communicated before the wire hits.
The investor conversation
Now the constituency that was not at the table but owns the theory being transacted: the funds’ limited partners. Begin with the formal layer, which is narrower than most sellers fear. A true minority, non-control stake typically does not require limited partner consent – the fund documents’ change-of-control and assignment provisions are generally written to trigger on control transfers, and the Advisers Act’s assignment concept likewise turns on actual control, with market practice treating well-structured minority deals as outside it (the analysis is facts-based; the 25% neighborhood is where the presumptions and the caution live, and the fund documents’ own definitions govern independently of the statute – both get read early, every time). Notice obligations, advisory committee protocols and side letter covenants can all be triggered short of consent, and the diligence of a stakes deal includes a document-by-document map of exactly what each fund’s papers require (our primer on side letters explains why that map has as many entries as the fund has bespoke deals).
Two mapping notes before the substance. Side letters are where the notice obligations actually live: Ownership change and key person-adjacent covenants negotiated investor by investor can require notification well below any control threshold, and the transfer restriction and confidentiality provisions in the fund documents constrain what may be shared in the buyer’s diligence – the map has as many entries as the fund has bespoke deals. And where the buyer is a strategic or sovereign rather than a dedicated stakes fund, a familiar wrinkle arrives: The stake often travels with fund commitments – the buyer anchoring the next flagship alongside its firm-level investment – which is commercially attractive and optically loaded, since capital that is both owner and investor sits on two sides of every future negotiation about fees, capacity and information. Disclose the linkage plainly; the investors who would mind discovering it are exactly the investors who will.
We will also name, because sophisticated readers know it anyway, a practice the market whispers about: Transactions are sometimes engineered – perimeters trimmed, structures interposed – specifically so that no consent is triggered and no disclosure obligation technically arises, keeping the buyer’s name out of the fund’s papers entirely. The engineering is usually lawful. It is also, in our view, a strategy with a shelf life: Investors’ diligence questionnaires now ask the ownership question directly, the fee transparency reporting standards reach economic participants beyond formal definitions, and a limited partner who learns of a silent stake in year three – from the trade press, where these things surface – has been handed a grievance far more expensive than the conversation would have been. The technical question is whether consent is required. The franchise question is whether you want your investors learning who owns your firm from someone other than you. Those are different questions, and the second one has only one good answer.
Which brings us to the substance of the conversation, because the real work is the alignment critique, and it deserves to be stated at full strength rather than managed: You sold a piece of the incentive we pay you to have. The carry exists to bind the manager to our outcomes; the fee exists to run the platform, not to be securitized; a buyer now stands between us and you, collecting a toll on economics we granted for a purpose; and some of you took money off the table besides. Every element of the good answer has appeared earlier in this primer, and it assembles as follows: Nothing about who manages your capital, makes decisions or owes you duties has changed – the buyer owes the funds’ investors no fiduciary duties, and the firm continues to owe all of them. Here is the primary/secondary split, and here is the $90 million of proceeds going into the funds as general partner commitment, which is more of our capital at risk beside yours than existed last quarter. Here is the succession this financed, which you have been asking about in every annual meeting for five years; here is the carry the working team retains, quantified; and here, for what it is worth, is the fact that a sophisticated institution just spent nine months diligencing our firm and paid a full price to be attached to it for a very long time.
Delivered before the leak, with those numbers, this conversation goes well far more often than sellers fear. Delivered after the leak, no numbers save it. One housekeeping rule belongs in the same breath: The transaction is the firm’s – every dollar of its costs is a management company expense, never a fund expense, and the data room gets built with the funds’ confidentiality obligations in mind, because limited partner names, returns and side letter terms are the investors’ information before they are the seller’s diligence exhibits.
The venture wrinkle
Venture capital arrived late to this market, and the reasons are the same reasons it is arriving now. Historically, the venture firm was a poor fit for the stakes model’s underwriting: The economics are carry-centric, so the durable fee stream – the thing buyers price best and pay most for – is the thing venture firms have least; fund sizes and therefore FRE are modest relative to franchise fame; the partnerships are small, personal and culturally allergic to outside shareholders; and, until recently, the founding generation had no succession problem because the founding generation had no intention of leaving.
Each of those premises is now eroding at the top of the market: The largest venture franchises have become diversified, registered, multistrategy platforms with fee streams a stakes buyer can finally model; the first founding generations of the modern venture era are, at last, aging into transition; and the seeding market described in our companion primer is producing, at the emerging end, exactly the firm-level economic interests that mature into stakes positions later – the two markets are converging into a single life cycle of outside ownership in venture firms. There is also a plumbing prerequisite that quietly gates the venture market: Stakes buyers underwrite audited, model-ready fee streams, and a lean exempt-reporting-adviser platform whose books were built for the partners’ eyes cannot be underwritten at all. Institutionalization precedes salability – the registered-adviser infrastructure, governed financials, documented comp and succession machinery – which means the venture firms capable of selling a stake are, almost by definition, the ones that have already made the institutional turn, and the transaction is as much a certificate of that turn as a financing of it.
What a venture stake prices, though, remains harder than its buyout cousin: The asset is disproportionately brand and access – deal flow, founder preference, the right to be in the best companies – which is real, valuable and viciously difficult to underwrite, because it walks out of the building every evening and can decline to return after a badly handled transition. A venture firm considering a stake sale should therefore expect the people terms – key person, succession, lockups, the migration of the franchise to named successors – to be the negotiation, with the economics almost an afterthought; and it should hold the brand covenants hardest of all, because in venture, the name is the collateral.
The regulatory map, in plain English
Short, as this map should be. The Advisers Act supplies the frame: An “assignment” of an advisory relationship – triggered by a change of actual control of the adviser – requires fund-level consent machinery, which is why stakes deals are sized and structured as true minorities and why the facts-and-circumstances control analysis, with its presumptions in the 25% neighborhood, is run at the term sheet stage rather than the closing dinner. Below that threshold, the workstreams are disclosure and hygiene: Form ADV ownership and control-person updates; the fund documents’ own consent, notice and transfer provisions, which bind regardless of what the statute would tolerate; and the standing fiduciary frame – the firm’s duties to its funds continue undiminished, the buyer acquires economics rather than duties, and conflicts introduced by the new owner’s other relationships (a stakes platform holds many managers; a strategic holds many interests) get identified and disclosed like any others. The hygiene list has two members that surprise sellers: Form ADV’s ownership schedules must be updated for the new interest-holders, which is one of the routes by which quiet deals become public ones; and the firm’s and funds’ credit documents – subscription facilities above all – carry their own change-of-control and ownership covenants, negotiated with lenders who defined “control” for credit purposes rather than Advisers Act purposes, so the lender consent map gets built alongside the fund consent map, early. Regulatory attention to the category has grown with the category, along familiar themes – fee transparency, valuation of the stakes themselves, conflicts management – and the sensible posture is the one this blog recommends everywhere: Paper the analysis, disclose the reality, and never let an examiner or an investor be the one to explain your ownership structure to you.
A worked example, because the proceeds tell the story
Numbers make the use-of-proceeds thesis concrete. Take a mid-market sponsor: $6 billion of assets across three active funds, $95 million of annual revenues, $40 million of fee-related earnings, a flagship about to come to market at $3 billion. The firm sells a 15% stake – management company economics plus a matching participation in future funds’ carry – for $150 million.
Now the only slide that matters: the money. Ninety million dollars funds the general partner commitments for the next flagship and the adjacent fund behind it – call it 2% of $4.5 billion of aggregate new commitments – taking the firm’s own capital at risk in its funds from roughly $45 million today to north of $130 million. Thirty-five million seeds the credit strategy the institution has been building toward, with a team hire the balance sheet could not previously carry. Twenty-five million – 17% of proceeds – is secondary, to the two founders, disclosed as such. The buyer’s entry economics are modest and honest: 15% of $40 million of FRE is $6 million a year of distributable cash – a 4% running yield on its $150 million – plus the carry option on funds not yet raised, which is to say the buyer paid a full price to bet on the firm’s future, not to strip its present.
Assemble the investor letter from those numbers and it writes itself: same team, same control, same duties; three times the GP commitment standing next to your capital; the succession and the credit platform you have heard about at two annual meetings, now funded; and founders who took a sixth of the proceeds off the table and rolled their careers on the rest. That is a stake sale as institution-building, arithmetic attached. Reverse the proportions – $110 million secondary, “strategic flexibility” for the remainder – and the same transaction, at the same price, is a different letter entirely, and everyone will know it. The terms were never the story – the proceeds were.
Practical market observations
Pulling the threads together, a few observations from the field.
- Decide the use of proceeds before the process, not after the price. It is the story, the internal contract and the standard you will be graded against at the next fundraise. A firm that cannot write the proceeds slide should not be taking meetings yet.
- Sell a percentage; keep the pen. Read the consent list in today’s voice and then in the voice of the partner class of 2045, for whom this document is an inheritance. Calibrate the people terms so they can migrate to successors, and buy the buyback at the entrance, where it is cheap.
- The perimeter is the deal. Entities, vintages, future funds, future strategies, the balance sheet – draw the line deliberately, price expansion rather than defaulting it in, and bring the tax advisers to the first whiteboard.
- Tell your investors before the market does. The formal consent analysis is usually short; the franchise analysis never is. The four-question narrative – control, split, incentives, retained carry – answered with numbers, before the leak, converts the alignment critique into an institution-building story. Engineered silence is lawful and, in our view, a depreciating asset.
- The deal prints a number, and the number never unprints. Prepare the partnership for what a market valuation does to every internal conversation – admissions, retirements, buy-sells, estates – before signing rather than after.
- Write the alternatives memo before the process – financings, internal solutions, patience – because your investors will ask what else you considered, and the answer shapes how the answer you chose is received.
- Design the internal transaction first – who sells, how comp is governed, what the partnership is told and when – because the external deal will be signed in months and lived with internally for decades.
- Check the credit agreements before the term sheet: The subscription lender’s change-of-control definition does not care about the Advisers Act’s, and a consent discovered late is leverage handed to the one party with no stake in your timeline.
- Firm expense, walled data, always: The transaction belongs to the management company, and the funds’ investors’ information is theirs.
- Diligence the buyer’s value-add in commitments closed, not meetings taken – and diligence its exit intentions out loud, because the market is aging into transfers, and your minority partner’s successor is a term of your deal whether or not it is written as one.
- And, in venture, hold the brand covenants hardest and expect the people terms to be the negotiation; the name is the collateral. Neither selling a piece of the firm nor holding it all is inherently right or wrong; unconsidered permanence is.
Conclusion
A GP stakes transaction is the moment the 100-year entity meets a 100-year investor, and the firm discovers whether it built what it claimed. Done well, it is genuinely what its best version promises: Outside capital converting a partnership’s success into an institution’s endurance – commitments funded, successions financed, growth capitalized – at a price set by the most sophisticated buyer of managers on earth, with alignment not diluted but demonstrably increased. Done carelessly, it is the founders’ exit wearing the institution’s clothes, discovered by the investors from the trade press and by the next generation from the consent list.
The questions, in the end, are the ones we opened with. What exactly is being sold? Where does the perimeter run? What will the money do? And can you show your limited partners the arithmetic with pride? And what does the buyer get besides economics – on terms the firm’s future leadership will thank you for, held by a partner whose own exit you have already imagined? These questions are related, but they are not the same, and the firms that answer all three before the first meeting are the ones for whom the transaction becomes what it should be: Not the day the firm sold a piece of itself, but the day the firm found out it had become the kind of institution worth buying.
The authors
